Patents by Inventor Guido Bold

Guido Bold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220185793
    Abstract: The pesent invention relates to compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof and their use for the prevention and treatment of oncovirus induced cancer in a subject.
    Type: Application
    Filed: April 9, 2020
    Publication date: June 16, 2022
    Inventors: Rajwinder Lehal, Guido Bold, Charlotte Urech, Vincent Zoete
  • Publication number: 20220169642
    Abstract: The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.
    Type: Application
    Filed: April 9, 2020
    Publication date: June 2, 2022
    Inventors: Rajwinder Lehal, Guido Bold, Charlotte Urech, Vincent Zoete
  • Patent number: 9890166
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: February 13, 2018
    Assignee: NOVARTIS AG
    Inventors: Jutta Blank, Guido Bold, Simona Cotesta, Vito Guagnano, Heinrich Rueeger, Andrea Vaupel
  • Patent number: 9624247
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (1) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: April 18, 2017
    Assignee: NOVARTIS AG
    Inventors: Jutta Blank, Guido Bold, Simona Cotesta, Vito Guagnano, Heinrich Rueeger
  • Patent number: 9550796
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: January 24, 2017
    Assignee: NOVARTIS AG
    Inventors: Heinrich Rueger, Jutta Blank, Vincent Bordas, Simona Cotesta, Guido Bold, Vito Guagnano, Andrea Vaupel
  • Publication number: 20160280719
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: November 20, 2014
    Publication date: September 29, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Vincent BORDAS, Simona COTESTA, Vito GUAGNANO, Heinrich RUEGER, Andrea VAUPEL
  • Publication number: 20160108047
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 26, 2014
    Publication date: April 21, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER, Andrea VAUPEL
  • Publication number: 20160102107
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 27, 2014
    Publication date: April 14, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER
  • Patent number: 8759517
    Abstract: The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: June 24, 2014
    Assignee: Novartis AG
    Inventors: Guido Bold, Pascal Furet, Vito Guagnano
  • Patent number: 8552002
    Abstract: The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: October 8, 2013
    Assignees: Novartis AG, IRM LLC
    Inventors: Qiang Ding, Nathanael Schiander Gray, Bing Li, Yi Liu, Taebo Sim, Tetsuo Uno, Guobao Zhang, Carole Pissot Soldermann, Werner Breitenstein, Guido Bold, Giorgio Caravatti, Pascal Furet, Vito Guagnano, Marc Lang, Paul William Manley, Joseph Schoepfer, Carsten Spanka
  • Publication number: 20130012704
    Abstract: The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Qiang DING, Nathanael Schiander GRAY, Bing LI, Yi LIU, Taebo SIM, Tetsuo UNO, Guobao ZHANG, Carole Pissot Soldermann, Werner BREITENSTEIN, Guido BOLD, Giorgio CARAVATTI, Pascal FURET, Vito GUAGNANO, Marc LANG, Paul W. MANLEY, Joseph SCHOEPFER, Carsten SPANKA
  • Publication number: 20130012476
    Abstract: The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Qiang DING, Nathanael Schiander GRAY, Bing LI, Yi LIU, Taebo SIM, Tetsuo UNO, Guobao ZHANG, Carole Pissot Soldermann, Werner BREITENSTEIN, Guido BOLD, Giorgio CARAVATTI, Pascal FURET, Vito GUAGNANO, Marc LANG, Paul W. MANLEY, Joseph SCHOEPFER, Carsten SPANKA
  • Patent number: 8293746
    Abstract: The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: October 23, 2012
    Assignee: Novartis AG
    Inventors: Guido Bold, Pascal Furet, Vito Guagnano
  • Publication number: 20120184561
    Abstract: The invention relates to compounds of the formula I, wherein the moieties R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, and salts thereof; as well as their use, methods of use for them and methods of their synthesis, and the like. The compounds are protein kinase inhibitors and can, inter alia, be used in the treatment of various proliferative diseases.
    Type: Application
    Filed: July 13, 2011
    Publication date: July 19, 2012
    Inventors: Guido BOLD, Pascal FURET, Vito GUAGNANO, Clive McCARTHY, Andrea VAUPEL
  • Publication number: 20120149661
    Abstract: The invention relates to tetra-substituted heteroarylic compounds of the formula (I) wherein X1, X3 and X4 are independently C or N, Y is C—H, N—H or N, wherein the total number of nitrogen atoms represented by X1, X3, X4 and Y is 1 or 2; rings A and B are independently selected from phenyl or pyridyl; R1, R4, R?, R?, n and m are as defined herein. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Application
    Filed: August 24, 2010
    Publication date: June 14, 2012
    Applicant: NOVARTIS AG
    Inventors: Guido Bold, Pascal Furet, Francois Gessier, Joerg Kallen, Joanna Hergovich Lisztwan, Keiichi Masuya, Andrea Vaupel
  • Publication number: 20120122857
    Abstract: The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
    Type: Application
    Filed: January 26, 2012
    Publication date: May 17, 2012
    Applicant: NOVARTIS AG
    Inventors: Guido BOLD, Andrea VAUPEL, Carole Pissot SOLDERMANN, Paul W. MANLEY
  • Publication number: 20120094958
    Abstract: The invention relates to a compound of formula (I) wherein the substituents are as described in the specification, which are useful as farnesyl pyrophosphate synthase modulators, e.g. in the treatment of proliferative diseases, to methods of manufacturing such compounds and to intermediates thereof.
    Type: Application
    Filed: February 26, 2009
    Publication date: April 19, 2012
    Applicant: NOVARTIS AG
    Inventors: Rene Amstutz, Guido Bold, Simona Cotesta, Wolfgang Jahnke, Andreas Marzinzik, Juliane Constanze Desiree Hartwieg, Silvio Ofner, Frédérik Stauffer, Johann Zimmermann
  • Patent number: 8133886
    Abstract: The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumor diseases.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: March 13, 2012
    Assignee: Novartis AG
    Inventors: Guido Bold, Andrea Vaupel, Carole Pissot Soldermann, Paul W Manley
  • Publication number: 20110301157
    Abstract: The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
    Type: Application
    Filed: August 17, 2011
    Publication date: December 8, 2011
    Inventors: Guido Bold, Hans-Georg Capraro, Giorgio Caravatti, Andreas Floersheimer, Pascal Furet, Paul W. Manley, Andrea Vaupel, Carole Pissot Soldermann, Francois Gessier, Christian Schnell, Amanda Jane Littlewood-Evans, Prasad Koteswara Kapa, Joginder S. Bajwa, Xinglong Jiang
  • Patent number: 8058276
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: November 15, 2011
    Assignee: Novartis AG
    Inventors: Guido Bold, Andrea Vaupel, Marc Lang